Spain

Hemgenix has now secured reimbursement in several European markets, with more talks ongoing. While the path to reimbursement has not always been easy, innovative access deals have helped to smooth the way.

New rules on health technology assessments in Spain make room for real-world evidence and early dialog.  

Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to prove cell therapy manufacturing doesn’t need to decelerate commercial viability.  

Bayer’s Midol and nonprofit Period. provide PeriodTalk campaign for awareness of the gaps in period education; “The M Factor” film coming day before World Menopause Day in October; Exeltis USA’s Blues Away provides postpartum mood support; and Doctor's Best Women's Collection includes menopause, sleep, digestive, heart and hair/skin/nails support products.

New rules on health technology assessments in Spain make room for real-world evidence and early dialogue.

Consumer health manufacturer Uriach has agreed to acquire Germany's Pascoe Naturmedizin and through a separate transaction France's Laboratoires Ineldéa, following investment by private-equity firm ICG.

J&J says it has “exhausted all current viable avenues” to get its antidepressant nasal spray Spravato reimbursed on England’s National Health Service, after NICE decided against re-appraising the drug following numerous funding rejections.

Recent consumer health appointments in Europe and Asia: Italian and Spanish OTC associations elect presidents and vice-presidents; P&G India names Hygiene & Heath Care CFO.

Hikma has announced the establishment of a Spanish subsidiary, marking the firm’s latest push into a new market alongside recent expansions in France and Canada. The moves are in line with a strategy laid out to Generics Bulletin several years ago by current CEO Riad Mishlawi.

Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.